Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objectives: This study assessed the needs, perceptions, and challenges associated with telemedicine in the treatment of oligoarticular/polyarticular juvenile idiopathic arthritis (oJIA/pJIA) and childhood-onset systemic lupus erythematosus (cSLE) in Japan.

Methods: A nationwide survey was conducted using Google Forms targeting members of the Japan College of Rheumatology, the Paediatric Rheumatology Association of Japan, and paediatricians affiliated with core paediatric specialty training facilities.

Results: Responses were received from 128 physicians with 77%, 50%, 27%, and 21% of patients travelling for more than one hour, crossing prefectural borders, coming from areas with limited specialised care, and residing in remote islands and regions, respectively. The JCR board-certified rheumatologists are more likely to treat these patients. Telemedicine was expected to reduce travel time (92.2%) and consultation time (92.2%), while concerns included patients' preference for in-person consultations (89.8%) and perceived differences in the quality of care (86.7%). Telemedicine was supported by 71.9% of respondents for stable oJIA/pJIA cases and 76.3% for stable cSLE cases.

Conclusions: Many physicians support telemedicine for patients with oJIA/pJIA or cSLE who travel long distances. Further studies should explore the quality differences between telemedicine and in-person consultations.

Download full-text PDF

Source
http://dx.doi.org/10.1093/mr/roaf075DOI Listing

Publication Analysis

Top Keywords

time 922%
8
in-person consultations
8
telemedicine
6
telemedicine paediatric
4
paediatric rheumatic
4
rheumatic diseases
4
diseases japan
4
japan national
4
national survey
4
survey physicians'
4

Similar Publications

Background: Select patients with metastatic clear-cell renal-cell carcinoma can be treated without systemic therapy, yet few studies have explored this population. We investigated the efficacy of metastasis-directed therapy without systemic therapy in oligometastatic clear-cell renal-cell carincoma.

Methods: This investigator-initiated single-arm, phase 2 trial enrolled patients aged 18 years or older with an Eastern Cooperative Oncology Group performance status of 0-2, histologically confirmed clear-cell renal-cell carcinoma, and one to five metastases.

View Article and Find Full Text PDF

Objectives: Vascular surgery (VS) is a high-risk specialty, with complex procedures and multi-morbid patients. Medicolegal claims offer insight into recurring clinical vulnerabilities. We aimed to analyse litigation trends in VS over the past decade in England, and the potential impact of the COVID-19 pandemic.

View Article and Find Full Text PDF

Background: Clinical notes house rich, yet unstructured, patient data, making analysis challenging due to medical jargon, abbreviations, and synonyms causing ambiguity. This complicates real-time extraction for decision support tools.

Objective: This study aimed to examine the data curation, technology, and workflow of the named entity recognition (NER) pipeline, a component of a broader clinical decision support tool that identifies key entities using NER models and classifies these entities as present or absent in the patient through an NER assertion model.

View Article and Find Full Text PDF

Purpose: Ensuring medication safety remains a pressing challenge in fragmented healthcare systems, particularly with the rapid growth of Internet Hospitals and limited pharmacist resources. Existing prescription review tools are often siloed and lack cross-institutional scalability. This study presents a cloud-based, dual-layer prescription review system (CEPR) designed to support provincial integration across Internet and outpatient care.

View Article and Find Full Text PDF

Introduction: Donanemab is an immunoglobulin G1 antibody that targets an N-terminal truncated form of amyloid beta present in mature plaques. Treatment-emergent (TE) anti-drug antibodies (ADAs) were quantified in donanemab-treated participants from two pivotal clinical trials, and effects of TE ADAs on donanemab pharmacokinetics, efficacy, and safety were assessed.

Methods: Data were pooled from the phase 2 TRAILBLAZER-ALZ (NCT03367403) and phase 3 TRAILBLAZER-ALZ 2 trials (NCT04437511).

View Article and Find Full Text PDF